Review,
Strategies to Improve Cannabidiol Bioavailability and Drug Delivery
Affiliations
- [1] CanPharmaConsulting, Nottingham NG9 3BB, England [NORA names: United Kingdom; Europe, Non-EU; OECD];
- [2] Fertin Pharm, Dandyvej 19, DK-7100 Vejle, Denmark [NORA names: Miscellaneous; Denmark; Europe, EU; Nordic; OECD];
- [3] Philip Morris Prod SA, PMI R&D, Quai Jeanrenaud 5, CH-2000 Neuchatel, Switzerland [NORA names: Switzerland; Europe, Non-EU; OECD];
- [4] Vectura Fertin Pharm, Basel, Switzerland [NORA names: Switzerland; Europe, Non-EU; OECD]
Abstract
The poor physicochemical properties of cannabidiol (CBD) hamper its clinical development. The aim of this review was to examine the literature to identify novel oral products and delivery strategies for CBD, while assessing their clinical implications and translatability. Evaluation of the published literature revealed that oral CBD strategies are primarily focused on lipid-based and emulsion solutions or encapsulations, which improve the overall pharmacokinetics (PK) of CBD. Some emulsion formulations demonstrate more rapid systemic delivery. Variability in the PK effects of different oral CBD products is apparent across species. Several novel administration routes exist for CBD delivery that may offer promise for specific indications. For example, intranasal administration and inhalation allow quick delivery of CBD to the plasma and the brain, whereas transdermal and transmucosal administration routes deliver CBD systemically more slowly. There are limited but promising data on novel delivery routes such as intramuscular and subcutaneous. Very limited data show that CBD is generally well distributed across tissues and that some CBD products enable increased delivery of CBD to different brain regions. However, evidence is limited regarding whether changes in CBD PK profiles and tissue distribution equate to superior therapeutic efficacy across indications and whether specific CBD products might be suited to particular indications.
